Skip to main content
Premium Trial:

Request an Annual Quote

LION Licenses New EST Clustering Software to Intervet: Mar 6, 2001 (rev. 2)

NEW YORK, March 6 – Lion Bioscience has licensed its soon-to-be launched EST clustering analysis software everEST, as well as genomeScout, its genome analysis software, to the Netherlands-based animal health company Intervet International, Lion said Tuesday.

Lion has also extended existing licenses for its SRS data integration platform and its bioScout genomic annotation system to Intervet.

“Intervet is a valuable customer with a broad experience in bioinformatics,” Christian Marcazzo, Lion’s director of product marketing, told GenomeWeb.

Lion said this new extended software licensing agreement will provide additional revenue, but Marcazzo declined to comment on its financial terms.

Intervet is the second company to license and implement everEST. Lion has also installed the software, which it will officially launch this spring, at Nestle.

EverEST is designed to retrieve data from Lion’s SRS platform and perform EST clustering on it. “For the first time, the user can retrieve biological information concerning ESTs and EST consensus sequences from all major biological databases,” Marcazzo said. “Built-in applications can be launched to further analyze consensus sequences, such as BLAST or LION's annotation application bioScout.”

The everEST system incorporates the StackPack clustering engine, which Lion non-exclusively licensed last fall from Electric Genetics in South Africa.

StackPack includes data management and visualization tools that enable researchers to rapidly cluster, align, and analyze high volumes of ESTs and partial-length sequences. These tools highlight variations in transcripts and can accelerate gene discovery, gene function analysis, expression analysis and drug development.

Lion has established partnerships with a number of Life Science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithkline, Janssen, Merck, Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Sumitomo Pharmaceuticals, and Tripos. SRS is currently used by more than 30 life science organizations to integrate more than 400 different databases, the company said.  
The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.